Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: A systematic review, meta- and cost-utility analysis

International Journal of Clinical Practice

Volumn 65, Issue 3, 2011, Pages 253-263

  Grosso, A M ^a,b   Bodalia, P N ^a,b   MacAllister, R J ^b   Hingorani, A D ^b   Moon, J C ^a   Scott, M A ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBASE; ESSENTIAL HYPERTENSION; HEALTH CARE COST; HEART FAILURE; HIDDEN MARKOV MODEL; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

EID: 79951618856     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02633.x     Document Type: Review

References (43)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ,. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57. (Pubitemid 43767064)
2. Mansia G, De BG, Dominiczak A, et al. ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135-232.
3. Jessup M, Brozena S,. Heart failure. N Engl J Med 2003; 348: 2007-18.
4. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51. (Pubitemid 23191415)
5. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
6. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203-8. (Pubitemid 28140291)
7. Lacourcie're Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-93.
8. Vauquelin G, Fierens F, Liefde IV,. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens 2006; 24: S23-30.
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
10. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. Chichester, UK: John Wiley & Sons Ltd, 2008.
11. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
12. Ades AE, Lu G, Higgins JPT,. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005; 25: 646-54. (Pubitemid 41667133)
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. (Pubitemid 37088507)
14. Anderson KM, Wilson PW, Odell PM, Kannel WB,. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
15. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB,. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-8.
16. Tzoulaki I, Liberopoulos G, Ioannidis JP,. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302: 2345-52.
17. Cupples LA, D'Agostino RB,. Framingham Heart Study, 30-year follow-up. Section 35. In:, Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Washington D.C.: DHHS, 1988, 65-209.
18. Sonnenberg FA, Beck JR,. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38. (Pubitemid 24013155)
19. Curtis L,. Unit Cost of Health and Social Care. Canterbury, Kent: Personal Social Services Research Unit, University of Kent, 2010.
20. Andersson OK, Neldam S,. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9. (Pubitemid 28137527)
21. Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM,. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract 2006; 60: 391-8.
22. Bakris G, Gradman A, Reif M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001; 3: 16-21. (Pubitemid 32605752)
23. Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52-7.
24. Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475-80. (Pubitemid 32640263)
25. Lacourciere Y, Asmar R,. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999; 12: 1181-7. (Pubitemid 30029280)
26. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22: 1186-203.
27. Willemsen JM, Rabelink TJ, Boer P, Gaillard CA,. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment. J Hum Hypertens 2004; 18: 857-63. (Pubitemid 39610367)
28. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6. (Pubitemid 37093917)
29. Weir RA, McMurray JJ, Puu M, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-added trial. Eur J Heart Fail 2008; 10: 157-63.
30. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-8.
31. British National Formulary (BNF) 58. London: BMJ and RPS Publishing, 2009. p. 108.
32. Staessen JA, Richart T, Wang Z, Thijs L,. Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension 2010; 55: 819-31.
33. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P,. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26: 1282-9.
34. NICE Clinical Guideline 34. Hypertension: Management of Hypertension in Adults in Primary Care (2006). http://guidance.nice.org.uk/CG34 (accessed 1 September 2010).
35. NICE Clinical Guideline 108 (update). Chronic Heart Failure (2010). http://www.nice.org.uk/nicemedia/live/13099/50514/50514.pdf (accessed 21 December 2010).
36. The Ontarget Investigators. The O, I. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
37. Shibata MC, Tsuyuki RT, Wiebe N,. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract 2008; 62: 1397-402.
38. Lakhdar R, Al-Mallah MH, Lanfear DE,. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181-8. (Pubitemid 351434594)
39. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71. (Pubitemid 37093916)
40. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000; 139: 609-17. (Pubitemid 30207785)
41. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7. (Pubitemid 30240502)
42. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52. (Pubitemid 27122456)
43. TEVA UK Limited Launches Losartan (2010). http://www.tevauk.com/generics/ news/view83 (accessed 1 September 2010).